Eze/Simva Switch Study in Diabetics (0653A-807)

• Status: Completed
• Trial end date: 2005-10-14
• Target enrollment: 0
• Participant gender: All

Summary

A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Atorvastatin; Atorvastatin Calcium; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Simvastatin

Criteria

Inclusion Criteria:

• Currently being treated with Atorvastatin 10 mg for at least 6 weeks

• Have Type 2 Diabetes

• Weight must be stable for more than 6 weeks before entering the study

Exclusion Criteria:

• Consume more than 14 alcoholic drinks per week.

• Pregnant or lactating

• Have taken another investigation drug within 3 months of starting this study

• History of congestive heart failure, heart attack, coronary artery bypass surgery

• Uncontrolled high blood pressure

• HIV positive

• History of cancer in the last 5 years